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ABSTRACT Myelin is a highly specialized membrane
unique to the nervous system that ensheaths axons to permit the
rapid saltatory conduction of impulses. The elaboration of a
compact myelin sheath is disrupted in a diverse spectrum of
human disorders, many of which are ofunknown etiology. The
X chromosome-linked human disorder Pelizaeus-Merzbacher
disease is a clinically and pathologically heterogeneous group of
disorders that demonstrate a striking failure ofoligodendrocyte
differentiation. This disease appears pathologically and genet-
ically to be similar to the disorder seen in the dysmyelinating
mouse mutant jimpy, which has a point mutation in the gene
encoding an abundant myelin protein, proteolipid protein
(PLP). We report that the molecular defect in one Pelizaeus-
Merzbacher family is likewise a point mutation in the PLP
gene. A single T -) C transition results in the substitution of a
charged amino acid residue, arginine, for tryptophan in one of
the four extremely hydrophobic domains of the PLP protein.
The identification of a mutation in this Pelizaeus-Merzbacher
family should facilitate the molecular classification and diag-
nosis of these X chromosome-linked human dysmyelinating
disorders.
mouse, which result in single amino acid substitutions in
PLP, are both associated with a lack of mature oligodendro-
cytes (18, 19).
The assignment of the PLP gene to the human X chromo-
some (20, 21) focused attention on an X-linked disorder of
myelination in man, Pelizaeus-Merzbacher disease. While
clinical and genetic heterogeneity for this disease has been
described, two well-documented forms, the classical and
connatal (Seitelberger) types, are both inherited as X chro-
mosome-linked recessive traits and feature nystagmus, athe-
tosis, tremors, and ataxia (22, 23). Patients with Pelizaeus-
Merzbacher disease share many of the traits of the jp muta-
tion, including the clinical signs of a dysmyelinating neuro-
logical disease, a lack of CNS myelin with a virtual absence
of PLP, and a paucity ofmature oligodendrocytes (22, 23). In
this report we identify a mutation in the PLP gene ofone such
Pelizaeus-Merzbacher family, a four-generation pedigree of
the classical type characterized extensively by Koeppen and
coworkers by using biochemical and immunocytochemical
techniques (24).
Proteolipid protein (PLP) constitutes half of the myelin
protein synthesized by oligodendrocytes in the central ner-
vous system (CNS), where it plays a structural role in the
architecture of the multilamellar myelin sheath (reviewed in
ref. 1). The developmental and tissue-specific expression of
PLP is coordinately controlled with the other myelin proteins
in the CNS (reviewed in refs. 2-5). In the peripheral nervous
system, PLP is the only myelin protein synthesized by
nonmyelinating Schwann cells, glial cells that enwrap but do
not myelinate axons.§ Moreover, PLP appears to be the only
myelin protein produced by myelinating Schwann cells that
is excluded from myelin (6, §). These observations have
prompted a reevaluation of the roles that PLP must assume
in glial cells. Analysis of dysmyelinating animal models has
reinforced the hypothesis that PLP performs a unique func-
tion in glial cells in addition to its structural role in the myelin
sheath. In the jimpy (jp) mouse, in which a mutation at a
splice site in the PLP gene creates aberrantly spliced tran-
scripts (7-12), the resulting absence of PLP has pronounced
effects on glial cell differentiation. Few mature oligodendro-
cytes are found injp CNS, despite the presence of excessive
numbers of precursor cells (13, 14). This block in oligoden-
drocyte maturation cannot be ascribed to the inability to form
a compact myelin sheath, since the failure of oligodendro-
cytes to myelinate in the dysmyelinating shiverer mouse
(which has a deletion in the gene encoding myelin basic
protein; refs. 15 and 16) does not result in the loss of
oligodendrocytes (reviewed in ref. 17). Point mutations in the
PLP gene of the canine shaking pup and the jimpymsd (jpmsd)
MATERIALS AND METHODS
A human genomic EMBL3 library constructed from a normal
donor was obtained from John Weis and was screened for
PLP-containing clones with human PLP cDNA probes
{PLPI.5 and PLPl.3 from ref. 6, nick-translated with [a-
32P]dCTP (Amersham)}. Of 106 plaques screened, 7 were
mapped in detail, as shown below the PLP gene in Fig. 1 (A52,
A91, A92, ASiA, A332, A271, A322). Exon-containing regions
were subcloned into pTZ18R and pTZ19R vectors (Pharma-
cia) for sequencing ofthe double-stranded plasmid DNA with
either the Klenow fragment or reverse transcriptase (GEM-
SEQ; Promega Biotec) as described by the manufacturer
(sequences not shown but available).¶
Two distinct pedigrees of Pelizaeus-Merzbacher families
are analyzed in this report. From the pedigree described by
Koeppen et al. (24), both the proband (designated PM2), who
died at the age of 18, and his affected nephew (PM3), who
displayed abnormalities at birth, were examined for mutation
at the PLP locus. From the pedigree originally reported by
Watanabe et al. (27), a 20-year-old affected male (J.H.;
Abbreviations: PLP, proteolipid protein; CNS, central nervous
system; PCR, polymerase chain reaction.
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FIG. 1. Structure of the human PLP gene. B, BamHI; R, EcoRI; H, HindIII. The intron/exon junctions in man and mouse were identical (19,
25, 26).
designated PM1 in this report), who upon examination by D.
Farrell displayed disturbances in electroencephalograms and
abnormal evoked responses (28), was characterized. DNA
from Pelizaeus-Merzbacher patients was prepared from fi-
broblasts donated by D. Farrell for PM1 (J.H.), and lympho-
blasts were obtained from the Coriell Institute (Camden, NJ)
for PM2 (GM7157) and PM3 (GM74478). Genomic libraries
from PM1 and PM3 DNA were constructed in the phage
AEMBL3 vector. Of 1.8 x 106 recombinants screened in the
PM1 library, 4 PLP-positive clones were obtained. One of
these, A56 containing all seven exons, was mapped and
subcloned into pTZ18R for sequencing. Of 106 recombinants
screened in the PM3 library, 2 PLP-positive clones were
selected, and the one containing exon 4, A93, was subcloned
into pTZ18 for sequencing. Sequencing of double-stranded
plasmid DNA was carried out with the modified phage T7
DNA polymerase (Sequenase; United States Biochemical) as
detailed by Tabor and Richardson (29). With the exception of
approximately 150 bp following the terminal polyadenylyla-
tion site, which was amplified by the polymerase chain
reaction (PCR) technique prior to sequencing, the PLP
exons, intron/exon junctions, and 1 kilobase (kb) of 5'
flanking sequence were sequenced from plasmids subcloned
from A56. Only exons 3 and 4 were sequenced from A93.
Exons 1-7 were amplified manually from normal or patient
genomic DNA by the PCR as described by Erlich and
coworkers (30, 31) with the following modifications using
20-mer oligonucleotide primers prepared on an Applied Bio-
systems synthesizer. Each 100-,l reaction mixture included
bovine serum albumin (170 ,g/ml) instead of gelatin; instead
of overlaying samples with mineral oil, we centrifuged the
samples after each denaturation step. Each cycle of a 30-
cycle program included a 1-min 95°C denaturation step,
followed by a 2-min, 55°C annealing step, and finally a 70°C
extension step, which was carried out for 2-6 min, depending
on the size of the amplified fragment. Thermus aquaticus
polymerase (Taq I) was purchased from Stratagene. The
amplified fragments ranged in size from 236 to 512 base pairs
(bp); a detailed map of their positions will be published
elsewhere (36). Primers were separated from amplified frag-
ments on Centricon 30 filtration units (Amicon) and were
sequenced by the method of Higuchi et al. (31) with a second
set of internal primers [20-mers that were phosphorylated
with [y-32P]ATP (Amersham)] and Sequenase (United States
Biochemical). To eliminate possible errors due to the Taq I
polymerase, samples were amplified in duplicate and both
samples were sequenced.
RESULTS AND DISCUSSION
Single Base Change in the PLP Gene of a Pelizaeus-
Merzbacher Patient. The structure of the normal PLP gene
was determined by (i) isolating PLP clones from a human
genomic library with human PLP cDNA probes sequenced
previously (6), (ii) mapping the positions of the seven exons,
and (iii) sequencing all exons and the intron/exon junctions
(Fig. 1). PLP is extremely conserved within and between
species both at the protein and DNA level (6, 7), which is
reflected in the absence of base changes between our se-
quence of the human PLP genomic DNA and the over 1300
bp published by Stoffel and coworkers (26) and by the
scarcity of restriction fragment length polymorphisms. More-
over, no differences have been observed in the coding or
noncoding regions of four unrelated individuals whose PLP
gene was sequenced from a genomic library, from a cDNA
library (6), or from PCR-amplified DNA (data not shown).
The degree of preservation of the PLP gene is striking and
makes two predictions: first, little variation in the amino acid
sequence of this integral membrane protein would be toler-
ated; and second, perhaps the DNA or RNA encoding PLP
directly plays a critical regulatory role in glial cells. The
former prediction has been borne out by analysis of thejpmsd
mutation, in which a conservative amino acid substitution in
an a-helical hydrophobic domain of PLP has drastic effects
on myelination (19).
A detailed analysis of the PLP gene in the Pelizaeus-
Merzbacher patients was undertaken both by the construc-
tion of genomic libraries and by PCR amplification of ge-
nomic DNA and sequencing of the amplified products. The
proband (PM2) and nephew (PM3) of the pedigree described
by Koeppen et al. (24) had only a single base change in their
PLP gene, a T -+ C transition in exon 4, which would
substitute an arginine (CGG) residue for tryptophan (TGG) at
amino acid 162 (Fig. 2). This alteration was confirmed by
sequencing a subclone from the phage A clone (A93) contain-
ing exon 4, which precludes the possibility that an error in
fidelity by the Taq I polymerase could account for the base
change observed in PCR-amplified DNA. An arginine sub-
stitution at this site may disrupt the structure of PLP, as the
introduced charged amino acid is located in one of the
hydrophobic domains that is devoid of charged amino acids.
PLP has four such hydrophobic a-helical domains, whose
interactions may be critical to the correct folding of the
protein and subsequent compaction of the myelin sheath (32).
The introduction of the charged arginine residue into one of
the hydrophobic a-helices may perturb these interactions.
Although we have not yet directly established that the single
base change in exon 4 creates the dysmyelinating phenotype
observed in this Pelizaeus-Merzbacher family, several lines
of evidence argue that the Trp-162 -* Arg change is respon-
sible. The lack of polymorphism at the PLP locus and the
marked interspecies conservation ofthe amino acid sequence
(i.e., man, mouse, and rat are identical for the amino acid
sequence of PLP (6, 7, 33), whereas cow (34) and dog (18)
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TTT GTG GGC ATC ACC TAT GCC CTG ACC GTT GTG





CTG GTG TTT GCC TGC TCT GCT GTG CCT
Leu Val Phe Ala Cys Ser Ala Val Pro
GTG TAC ATT TAC TTC AAC ACC TGG ACC ACC TGC
Val Tyr Ile Tyr Phe Asn Thr Trp Thr Thr Cys
CAG TCT ATT GCC TTC CCC AGC AAG ACC TCT GCC
Gln Ser Ile Ala Phe Pro Ser Lys Thr Ser Ala
AGT ATA GGC AGT CTC TGT GCT GAC GCC AGA ATG
Ser Ile Gly Ser Leu Cys Ala Asp Ala Arg Met
TAT G
Tyr G(ly)
FIG. 2. The PLP gene of patients PM2 and PM3 contains a point
mutation. Arrows note the sequence difference found in the genes of
patients PM2 and PM3, where a cytidine residue is evident in the
position of a thymidine residue in the normal control (S.G.). The
exon 4DNA sequence is shown with the encoded amino acids below,
illustrating the Trp -+ Arg substitution that would result in abnormal
PLP in patients PM2 and PM3. The PM2 and PM3 DNA amplified
from exon 4 has an Fnu4HI site (5'-GCNGC-3'), which was absent
from the normal control.
differ by two and one conservative amino acids, respectively)
suggest that any amino acid change may affect PLP function.
Moreover, PLP was absent in the PM2 patient, while low
levels of the other myelin proteins (myelin basic protein,
myelin-associated glycoprotein, and 2',3'-cyclic-nucleotide
3'-phosphodiesterase) were detectable (24). Finally, both the
biochemical course and clinical course of the disease in this
Pelizaeus-Merzbacher family mimic those observed in thejp
mouse, in which the splice site mutation in the PLP gene
creates an aberrant PLP protein (7-12).
Diagnosis of Other X Chromosome-Linked Dysmyelinating
Disorders. Prenatal diagnosis of this untreatable degenerative
disorder could be made available for the PM2/PM3 family,
either by taking advantage of the fact that the mutation
creates a new restriction site (Fnu4HI) or by PCR-amplifying
and sequencing exon 4. Unfortunately, the conserved nature
of the PLP gene and the experience with jp, jpmsd, and
shaking pup, in which each mutation occurs at a distinct site
of the PLP gene, suggest that each Pelizaeus-Merzbacher
pedigree may have a different mutation in the PLP gene.
Indeed, an altered profile ofPLP-positive bands on Southern
blots has been reported for another candidate of Pelizaeus-
Merzbacher disease (35), and an unrelated family displayed
a novel point mutation in the PLP gene (36), which hints at
a genetic heterogeneity that may complicate the analysis of
the putative mutation in any pedigree. However, the modest
size of the PLP gene should permit the analysis of all
mutations affecting this gene and clarify whether Pelizaeus-
Merzbacher disease is as genetically heterogeneous as the
half-dozen variants of the disease would imply. Historically,
pedigrees with X-linked (classical, connatal types), autoso-
mal recessive (variant with Cockayne's disease, variant with
patchy demyelination), or autosomal dominant (adult Lo-
wenberg-Hill type) patterns of inheritance have been lumped
into the Pelizaeus-Merzbacher category based on the pleio-
tropic clinical findings (22, 23). The discovery of an altered
PLP gene in the classical form of Pelizaeus-Merzbacher
disease (Fig. 2) invites inspection of the PLP gene in some of
these variant forms of Pelizaeus-Merzbacher disease. The
molecular dissection of the PLP gene would be especially
welcome for cases with sex-linked inheritance that lack a
pathological analysis because, even when magnetic reso-
nance imaging is available to illuminate the lack of myelin,
only an invasive biopsy or autopsy can document the reduc-
tion in differentiated oligodendrocytes and the sparse myelin
islands characteristic of Pelizaeus-Merzbacher disease.
We have analyzed the PLP gene from one such variant of
Pelizaeus-Merzbacher disease, a six-generation Pelizaeus-
Merzbacher family with over 23 affected males originally
described by Watanabe et al. (27) and further studied by
Wilkus and Farrell (28). This pedigree is a textbook case of
Pelizaeus-Merzbacher disease both clinically and geneti-
cally, but a curious pathology was noted in a 3-month-old
affected infant from this family. Apparently normal myelin
was present, but a significant amount of the myelin sheaths
were organized into ball-like structures in the oligodendro-
cyte perikarya and terminal processes (27). The PLP gene
from this pedigree (PM1) was unaltered for over 4 kb of
coding and noncoding sequence. In addition, analysis by
Southern blot hybridization of restriction digests of PM1
genomic DNA probed with human PLP cDNA failed to
reveal any differences from the normal gene (Fig. 3). A
detailed restriction map of a phage A genomic clone (A56)
from patient PM1, which contained exons 1-7, also failed to
uncover any differences from the normal gene (data not
shown). Subcloning and sequencing of this A clone (A56)
showed that the PLP gene of the PM1 patient was identical
to the normal gene (data not shown) in all coding regions, in
intron/exon junctions, in polyadenylylation sites, and for >1
kb 5' to the translation initiation site. These results indicate
that there is another locus on the X chromosome affecting
myelination in addition to the PLP locus. None of the other
major myelin genes (myelin basic protein; myelin-associated
glycoprotein, PO) are known to map to the X chromosome,
leaving open for consideration a less abundant glial-specific
protein whose function would be essential for the mainte-
nance of normal myelin sheaths. The pedigree of Watanabe
et al. (27) presumably contains a mutation at this second locus
on the X chromosome, which would define genetically an
X-linked dysmyelinating disease distinct from the classical
and connatal forms of Pelizaeus-Merzbacher disease.
Nosology of the Inborn Errors of Myelin Metabolism. My-
elin disorders with autosomal inheritance (22) are candidates
for mutation in any of the genes encoding myelin proteins
other than PLP. These human dysmyelinating disorders
would be expected to present with overlapping clinical symp-
toms, but pathologically would not display the hallmark of
mutation at the PLP locus, which is the lack of mature
oligodendrocytes. Now that many of the genes encoding
myelin proteins have been cloned (PLP, myelin basic protein,
myelin-associated glycoprotein, Po, P2, and 2',3'-cyclic-
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FIG. 3. The structure of the PLP gene is preserved in two
Pelizaeus-Merzbacher pedigrees. DNA (15 pg per slot) from Peliza-
eus-Merzbacher patients or an unaffected control (S.G.) was di-
gested with EcoRI (lanes E), BamHI (lanes B), HindIII (lanes H), or
Pst I (P), electrophoresed on a 0.6% agarose gel, blotted onto
nitrocellulose, and probed with a 32P-labeled, nick-translated PLP
cDNA of 1.5 kb (ref. 6). The sizes in kb ofthe phage A HindIll marker
are shown on the left. The PM3 (Left) and PM1 (Right) samples
generate the same pattern of bands as the normal control (Center).
nucleotide 3'-phosphodiesterase; refs. 2-5) and mapped to
their respective human chromosomes, molecular biological
techniques may be applied where scant biochemical data is
available. In particular, the further molecular analysis of the
sex-linked disorders of myelination, clinically and patholog-
ically classified as Pelizaeus-Merzbacher disease, offers the
potential for accurate diagnosis and prenatal testing in af-
fected families. The X-linked inborn errors of myelin metab-
olism represent at least two loci on the X chromosome critical
to myelination, one of which encodes PLP. These two
disorders can be readily discriminated pathologically by the
extent of myelination. Authentic Pelizaeus-Merzbacher pa-
tients should present with only residual amounts of sudano-
philic cells (mature oligodendrocytes that have elaborated a
myelin sheath, which absorbs the Sudan black dye). Our
results predict that all patients with the genetics, clinical
history, and pathology of the classical type of Pelizaeus-
Merzbacher disease will have a mutation at the PLP locus.
We propose restricting the term Pelizaeus-Merzbacher to
these patients to reduce the confusion attendant with group-
ing a diverse array of myelin disorders under the Pelizaeus-
Merzbacher rubric.
Note Added in Proof. A third Pelizaeus-Merzbacher family was
recently found by M. E. Hodes and coworkers (37) to have a distinct
mutation at the PLP locus, a proline -- leucine substitution at amino
acid 14.
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